X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (76714) 76714
Book Review (5937) 5937
Publication (3608) 3608
Conference Proceeding (400) 400
Newsletter (255) 255
Book Chapter (250) 250
Dissertation (167) 167
Magazine Article (71) 71
Government Document (67) 67
Newspaper Article (41) 41
Paper (17) 17
Book / eBook (11) 11
Trade Publication Article (6) 6
Web Resource (6) 6
Reference (5) 5
Data Set (3) 3
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (61498) 61498
humans (49448) 49448
doxorubicin (33958) 33958
female (28501) 28501
doxorubicin - administration & dosage (21900) 21900
male (21879) 21879
oncology (20860) 20860
animals (18875) 18875
middle aged (17486) 17486
antineoplastic combined chemotherapy protocols - therapeutic use (17036) 17036
chemotherapy (16282) 16282
cancer (15722) 15722
adult (14877) 14877
aged (13658) 13658
doxorubicin - pharmacology (12915) 12915
doxorubicin - therapeutic use (10092) 10092
mice (10047) 10047
pharmacology & pharmacy (9078) 9078
cyclophosphamide - administration & dosage (8738) 8738
anthracyclines (8389) 8389
cell line, tumor (7941) 7941
treatment outcome (7225) 7225
nanoparticles (7061) 7061
vincristine - administration & dosage (6768) 6768
drug delivery systems (6588) 6588
doxorubicin - adverse effects (6297) 6297
apoptosis (6276) 6276
breast neoplasms - drug therapy (6266) 6266
therapy (6178) 6178
drugs (5543) 5543
rats (5392) 5392
combined modality therapy (5365) 5365
breast cancer (5143) 5143
antineoplastic combined chemotherapy protocols - administration & dosage (5138) 5138
antineoplastic agents - pharmacology (5121) 5121
prognosis (5104) 5104
antineoplastic combined chemotherapy protocols - adverse effects (5100) 5100
tumors (4943) 4943
cisplatin - administration & dosage (4606) 4606
adriamycin (4507) 4507
adolescent (4406) 4406
biochemistry & molecular biology (4313) 4313
antineoplastic agents - therapeutic use (4237) 4237
cell survival - drug effects (4197) 4197
expression (4127) 4127
dose-response relationship, drug (4097) 4097
hematology (4082) 4082
analysis (4076) 4076
care and treatment (4012) 4012
antineoplastic agents - administration & dosage (4008) 4008
abridged index medicus (3997) 3997
chemistry, multidisciplinary (3969) 3969
toxicity (3919) 3919
prednisone - administration & dosage (3871) 3871
cells (3810) 3810
cyclophosphamide (3752) 3752
cisplatin (3725) 3725
apoptosis - drug effects (3698) 3698
time factors (3686) 3686
neoplasm staging (3683) 3683
doxorubicin - chemistry (3660) 3660
drug resistance (3611) 3611
in-vitro (3541) 3541
doxorubicin - toxicity (3539) 3539
breast neoplasms - pathology (3520) 3520
cyclophosphamide - therapeutic use (3519) 3519
drug-delivery (3497) 3497
antibiotics, antineoplastic - pharmacology (3459) 3459
aged, 80 and over (3357) 3357
survival rate (3326) 3326
drug administration schedule (3302) 3302
research (3281) 3281
retrospective studies (3275) 3275
paclitaxel (3255) 3255
disease-free survival (3225) 3225
tumor cells, cultured (3213) 3213
vincristine - therapeutic use (3139) 3139
antibiotics, antineoplastic - administration & dosage (3130) 3130
drug delivery (3125) 3125
doxorubicin - analogs & derivatives (3102) 3102
cytotoxicity (3030) 3030
vehicles (3027) 3027
liposomes (3023) 3023
doxorubicin - pharmacokinetics (2996) 2996
survival (2988) 2988
cardiotoxicity (2951) 2951
carcinoma (2947) 2947
neoplasms - drug therapy (2933) 2933
methotrexate - administration & dosage (2906) 2906
follow-up studies (2898) 2898
health aspects (2857) 2857
nanoscience & nanotechnology (2831) 2831
survival analysis (2829) 2829
drug resistance, neoplasm (2737) 2737
fluorouracil - administration & dosage (2736) 2736
micelles (2727) 2727
in-vivo (2661) 2661
cell biology (2649) 2649
child (2642) 2642
drug therapy (2627) 2627
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (10) 10
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Circulation Desk (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Online Resources - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (70599) 70599
Japanese (2602) 2602
Chinese (1083) 1083
German (887) 887
French (729) 729
Russian (525) 525
Spanish (355) 355
Italian (245) 245
Polish (203) 203
Korean (92) 92
Portuguese (71) 71
Hungarian (50) 50
Czech (47) 47
Ukrainian (28) 28
Turkish (25) 25
Dutch (24) 24
Croatian (15) 15
Hebrew (15) 15
Serbian (15) 15
Persian (10) 10
Swedish (8) 8
Danish (7) 7
Lithuanian (7) 7
Bulgarian (5) 5
Finnish (4) 4
Norwegian (4) 4
Slovak (4) 4
Romanian (3) 3
Arabic (2) 2
Bosnian (2) 2
Indonesian (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chemical Communications: Chem Comm, ISSN 1359-7345, 12/2013, Volume 50, Issue 8, pp. 1000 - 1002
The polyacrylic acideolitic imidazolate framework-8 (PAAIF-8) nanoparticles (NPs) were first fabricated using a facile and simple route. It is worthwhile... 
Doxorubicin
Journal Article
Hematological Oncology, ISSN 0278-0232, 02/2018, Volume 36, Issue 1, pp. 68 - 75
The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of “R‐COMP” combination... 
diffuse large B‐cell lymphoma | cardiotoxicity | non‐pegylated liposomal doxorubicin | non-pegylated liposomal doxorubicin | diffuse large B-cell lymphoma | CYCLOPHOSPHAMIDE | RITUXIMAB R-COMP | CONVENTIONAL DOXORUBICIN | ONCOLOGY | ENCAPSULATED DOXORUBICIN | METASTATIC BREAST-CANCER | VINCRISTINE | NON-HODGKIN-LYMPHOMA | CHOP | HEMATOLOGY | ELDERLY-PATIENTS | Doxorubicin - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Comorbidity | Humans | Male | Treatment Outcome | Polyethylene Glycols - therapeutic use | Polyethylene Glycols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Heart Diseases - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Doxorubicin - analogs & derivatives | Female | Italy | Aged | Heart Diseases - drug therapy | Doxorubicin - pharmacology | Doxorubicin - administration & dosage | Polyethylene Glycols - pharmacology | Care and treatment | Anthracyclines | Cyclophosphamide | Analysis | Atrial fibrillation | Clinical trials | Product development | Prednisone | Disorders | Rituximab | Lymphoma | Patients | Doxorubicin | Vincristine | Heart rate | Fibrillation | Ischemia | Lymphocytes B | Remission | Lymphomas | Ventricle | Bayesian analysis | Heart diseases | Hypertrophy | Ejection | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 06/2016, Volume 16, Issue 1, pp. 352 - 352
Journal Article
Biomaterials, ISSN 0142-9612, 2016, Volume 101, pp. 131 - 142
Abstract Caspase-activated prodrug chemotherapy is introduced and demonstrated using the composite nanoparticles (NPs), which deliver doxorubicin (DOX) and... 
Advanced Basic Science | Dentistry | Heparin | Doxorubicin-induced apoptosis-targeted chemotherapy | Doxorubicin prodrug | Caspase-3 | Doxorubicin | The composite nanoparticles | MATERIALS SCIENCE, BIOMATERIALS | ACID | DRUG-DELIVERY | INDUCED APOPTOSIS | ENGINEERING, BIOMEDICAL | CARDIOTOXICITY | chemotherapy | CHILDREN | BREAST-CANCER | HETEROGENEITY | THERAPY | MOUSE MODEL | Doxorubicin-induced apoptosis-targeted | Neoplasms - metabolism | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Heparin - metabolism | Nanoparticles - analysis | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Heparin - administration & dosage | Heparin - therapeutic use | Male | Heparin - pharmacokinetics | Prodrugs - metabolism | Tissue Distribution | Nanoparticles - therapeutic use | Nanoparticles - metabolism | Doxorubicin - metabolism | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Animals | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Cell Line, Tumor | Mice | Nanoparticles - administration & dosage | Prodrugs - therapeutic use | Antibiotics, Antineoplastic - metabolism | Nanoparticles | Chemotherapy | Anthracyclines | Measuring instruments | Imaging systems | High performance liquid chromatography | Cancer | Index Medicus | Drugs | Effectiveness | Activation | Chemical compounds | Apoptosis | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Journal Article
ACS Nano, ISSN 1936-0851, 02/2013, Volume 7, Issue 2, pp. 994 - 1005
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 2012, Volume 423, Issue 1, pp. 16 - 25
One of the new strategies to improve cancer chemotherapy is based on new drug delivery systems, like the polyethylene glycol-coated superparamagnetic iron... 
Superparamagnetic iron oxide nanoparticles (SPION) | Polyethylene glycol | Release kinetics | Intracellular distribution | Doxorubicin (DOX) | IRON-OXIDE NANOPARTICLES | CELLS | TOXICITY | CANCER | CHEMOTHERAPY | EXPERIENCES | PHARMACOLOGY & PHARMACY | ANTHRACYCLINES | Humans | Biological Availability | Cytoplasm - metabolism | Ferric Compounds - chemistry | Polyethylene Glycols - chemistry | Chlorides - chemistry | Nitrates - chemistry | Cell Nucleus - metabolism | Isoelectric Point | Light | Surface Properties | Inhibitory Concentration 50 | Doxorubicin - metabolism | Ferrous Compounds - chemistry | Scattering, Radiation | Doxorubicin - administration & dosage | Propylamines - chemistry | Cell Survival - drug effects | Microscopy, Electron, Transmission | Silanes - chemistry | Magnetite Nanoparticles - ultrastructure | Static Electricity | Chemistry, Pharmaceutical | Doxorubicin - pharmacokinetics | Particle Size | Magnetite Nanoparticles - chemistry | Microscopy, Fluorescence - methods | Magnetics - methods | Cell Line, Tumor | Drug Delivery Systems - methods | Doxorubicin - pharmacology | Hydrogen-Ion Concentration | Nanoparticles | Anthracyclines | Ferric oxide | Polyols | Index Medicus | Bioengineering | Cell Nucleus/metabolism | Magnetite Nanoparticles/chemistry | Cell Survival/drug effects | Doxorubicin/pharmacokinetics | Biomaterials | Life Sciences | Imaging | Doxorubicin/administration & dosage | Medication | Microscopy, Fluorescence/methods | Drug Delivery Systems/methods | Pharmaceutical sciences | Cancer
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 02/2011, Volume 22, Issue 2, pp. 136 - 147
Galactosyl-terminated drug carriers are known to enhance drug accumulation in the liver, while possible accompanying hepatic toxicity is usually not clarified.... 
α,β-poly[(2-hydroxyethyl)-L-aspartamide] | doxorubicin | galactosyl | hepatotoxicity | hepatocellular carcinoma | POLYMER-BOUND DOXORUBICIN | PERFORMANCE | CARDIOTOXICITY | SYSTEMIC THERAPY | LACTOSAMINATED HUMAN ALBUMIN | alpha, beta-poly[(2-hydroxyethyl)-L-aspartamide] | PHARMACOKINETICS | ONCOLOGY | N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS | ADRIAMYCIN | CONJUGATE | PHARMACOLOGY & PHARMACY | PHASE-I | Antibiotics, Antineoplastic - toxicity | Humans | Peptides - pharmacokinetics | Drug Carriers - administration & dosage | Drug Carriers - toxicity | Peptides - administration & dosage | Galactose - analogs & derivatives | Liver Neoplasms, Experimental - metabolism | Peptides - toxicity | Doxorubicin - analogs & derivatives | Female | Antibiotics, Antineoplastic - pharmacokinetics | Heart Diseases - chemically induced | Chemical and Drug Induced Liver Injury - etiology | Doxorubicin - administration & dosage | Galactose - pharmacokinetics | Doxorubicin - pharmacokinetics | Doxorubicin - toxicity | Mice, Inbred ICR | Antibiotics, Antineoplastic - administration & dosage | Animals | Liver Neoplasms, Experimental - drug therapy | Cell Line, Tumor | Galactose - toxicity | Drug Carriers - pharmacokinetics | Mice | HeLa Cells | Galactose - administration & dosage | Toxicity Tests | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Chemical Communications : Chem Comm, ISSN 1359-7345, 01/2019, Volume 55, Issue 39, pp. 5607 - 5610
Highly cytotoxic agents have found an important niche in targeted anticancer therapy. Here we develop a new light release strategy for the targeting of one of... 
Toxicity | Doxorubicin
Journal Article
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 07/2014, Volume 103, Issue 7, pp. 2157 - 2165
Journal Article